Table 1.
Baseline demographics of the Pulmonary Hypertension Association Registry
| Meth-APAH (n = 118) | IPAH (n = 423) | |
|---|---|---|
| Age, yr (n = 541) | 47.5 ± 9.2 | 55.5 ± 17.2 |
| Body mass index, kg/m2 (n = 522) | 30.4 ± 6.5 | 31.1 ± 7.8 |
| Sex, M (n = 541) | 44 (37) | 100 (24) |
| Uninsured (n = 541) | 6 (5) | 7 (2) |
| Never married (n = 531) | 35 (30) | 72 (17) |
| College graduate (n = 533) | 20 (17) | 141 (34) |
| Unemployed (n = 541) | 52 (44) | 88 (21) |
| Ever-smoker (n = 535) | 84 (72) | 200 (48) |
| Current alcohol use (n = 532) | 38 (32) | 152 (37) |
| Ever use of methamphetamines (n = 539) | ||
| Yes | 106 (91) | 27 (6) |
| No | 8 (7) | 389 (92) |
| Declined to answer | 3 (3) | 6 (1) |
| Mean follow up time, d (n = 437) | 390.9 ± 352.7 | 414.3 ± 358.3 |
| Incident diagnosis of PAH (n = 540) | 54 (46) | 212 (51) |
| Race/ethnicity (n = 509) | ||
| Non-Hispanic white | 79 (73) | 300 (75) |
| Hispanic | 18 (17) | 43 (11) |
| Black | 6 (6) | 51 (13) |
| Asian | 5 (5) | 7 (2) |
| Taxable income per year (n = 442) | ||
| Less than $50,000 | 84 (84) | 172 (50) |
| $50,000–$100,000 | 12 (12) | 90 (26) |
| $100,000–$150,000 | 2 (2) | 47 (14) |
| Greater than $150,000 | 2 (2) | 33 (10) |
| U.S. census region (n = 541) | ||
| Northeast | 4 (3) | 76 (18) |
| Midwest | 7 (6) | 79 (19) |
| South | 9 (8) | 156 (37) |
| West | 98 (83) | 112 (27) |
| WHO functional class (n = 506) | ||
| Class 1 | 10 (9) | 41 (10) |
| Class 2 | 32 (28) | 134 (34) |
| Class 3 | 62 (54) | 193 (49) |
| Class 4 | 11 (10) | 23 (6) |
| REVEAL lite 1 risk category (n = 231) | ||
| Low risk | 27 (59) | 94 (51) |
| Intermediate risk | 12 (26) | 45 (24) |
| High risk | 7 (15) | 46 (25) |
| Six-minute walk distance, m (n = 451) | 375.8 ± 118.0 | 343.3 ± 139.3 |
| B-type natriuretic peptide, pg/ml (n = 304) | 104 [32.5–370] | 114 [41–332] |
| Creatinine, mg/dl (n = 523) | 0.9 [0.8–1.1] | 0.9 [0.8–1.1] |
| Therapy at enrollment (n = 538) | ||
| Digoxin | 13 (11) | 33 (8) |
| On PAH-specific therapy | 100 (86) | 370 (88) |
| Dual combination therapy | 60 (52) | 216 (52) |
| Triple therapy | 13 (11) | 86 (20) |
| Parenteral prostacyclin | 7 (6) | 117 (28) |
| Oxygen supplementation | 30 (26) | 203 (48) |
Definition of abbreviations: IPAH = idiopathic pulmonary arterial hypertension; Meth-APAH = methamphetamine-associated pulmonary arterial hypertension; PAH = pulmonary arterial hypertension; WHO = World Health Organization.
Baseline demographic and clinical parameters of Meth-APAH versus IPAH in the Pulmonary Hypertension Association Registry at the time of enrollment in the registry. Data are presented as mean ± standard deviation for normally distributed continuous variables, as median [interquartile range] for nonnormally distributed continuous variables, and n (%) for categorical variables. REVEAL Lite 1 risk score calculated from the REVEAL risk calculator (22).